Events & Presentations Corporate Presentation Date Documents November 19, 2020 Corporate Presentation Upcoming Events There are currently no events to display. Archived Investor Events and Presentations Archived Scientific Presentations There are currently no events to display. Date Documents December 6, 2020 Complete Responses in Relapsed/ Refractory AML Patients on a Weekly Dosing Schedule of Vibecotamab, a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Results of a Phase 1 Study November 9, 2020 Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors November 9, 2020 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors November 9, 2020 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors November 9, 2020 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents October 2, 2020 NANETS 2020: Preliminary Safety, PK/PD, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Patients With Advanced Neuroendocrine Tumors June 22, 2020 AACR 2020: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity June 22, 2020 AACR 2020: Affinity tuned XmAb® 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells June 22, 2020 AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies June 22, 2020 AACR 2020: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models December 9, 2019 ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL March 4, 2019 Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format December 3, 2018 ASH 2018: Complete Responses in r/r AML Patients on a Weekly Dosing Schedule of XmAb®14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study December 3, 2018 ASH 2018: Regulatory T cell selective IL-2-Fc fusion proteins for the treatment of autoimmune diseases November 9, 2018 SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation November 9, 2018 SITC 2018: An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure October 21, 2018 ACR 2018: Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE) April 18, 2018 AACR 2018: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure April 16, 2018 AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation November 13, 2017 SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation November 13, 2017 SITC 2017: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation November 8, 2017 ACR 2017: Final Results from Phase 2 Study of XmAb 5871 in IgG4-Related Disease June 16, 2017 EULAR 2017: Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease April 4, 2017 AACR 2017: Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors April 4, 2017 AACR 2017: IL 15/IL 15Ra; heterodimeric Fc-fusions with extended half-lives April 4, 2017 AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation November 13, 2016 Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease November 13, 2016 Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation November 9, 2016 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation May 18, 2016 American Thoracic Society: ATS Conference 2016: A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195 June 12, 2015 European League Against Rheumatism (EULAR) 2015 Annual Meeting Poster: A Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis December 8, 2014 American Society of Hematology 2014 Annual Meeting Poster: Anti-CD38 × Anti-CD3 Bispecific Antibodies in Multiple Myeloma Chu, et al, Abstract ID# 4727 December 7, 2014 American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111 December 7, 2014 Xencor American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD123 x Anti-CD3 Bispecific Antibodies in Acute Myleogenous Leukemia Chu, et al, Abstract ID# 2316
